This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Prospective Study of Belated Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells. (RESPPEDHEM)

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT02032381
First received: December 9, 2013
Last updated: October 11, 2016
Last verified: October 2016
  Purpose
Hematopoietic stem cell transplantation (HSCT) is used to treat an expanding array of malignant and non-malignant disorders. This is a prospective multicenter study, in pediatric allo-BMT recipients to analyze the spectrum of noninfectious pulmonary complications (PC), to evaluate the prevalence and course of PFT abnormalities before and after transplant, and to detect risk factor for PC.

Condition Intervention
Bone Marrow Transplant Infection Bronchiolitis Obliterans Chronic Respiratory Insufficiency Organizing Pneumonia Pulmonary Cytolytic Thrombi Other: late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Prospective Study of Late Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Presence of belated non-infectious pulmonary complications [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Presence of risk factors for belated non-infectious pulmonary complications [ Time Frame: 3 years ]
  • Survival three years [ Time Frame: 3 years ]
  • Severity of respiratory disease [ Time Frame: 3 years ]

Estimated Enrollment: 500
Study Start Date: January 2014
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
allogeneic hematopoietic stem cell
The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
Other: late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.

Detailed Description:

It's a multicenter prospective study in France. All children under 18 years are included, just before the HSCT. The functional test before the HSCT at 6, 12, 18, 24, 30 and 36 months will be collected and a cardiopulmonary exercise test is done one and three years after the HSCT. Thoracic tomodensitometry is done before the HCT and after at 6, 12, 24 and 36 months.

All data will be collected upon the HSCT, the infections before and after the HSCT, the respiratory symptoms, and the treatment. Bronchia alveolar lavage and serum will be collected and frozen during the study.

The inclusion will be done during two years and children will be following during three years.

The purpose is to evaluate the prevalence, the course of PFT abnormalities before and after transplant, and to detect risk factor for PC.

  Eligibility

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: from birth to 18 years
  • Patient to be treated by allogeneic hematopoietic stem cell - Parents who have given their signed consent for the study
  • Affiliation to a social security scheme

Exclusion Criteria:

  • non exclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02032381

Contacts
Contact: Houdouin veronique, MD PHD 0140033678 veronique.houdouin@rdb.aphp.fr

Locations
France
Houdouin véronique Recruiting
Paris, France, 75019
Contact: houdouin véronique, MD PHD    0140033678    veronique.houdouin@rdb.aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Houdouin Véronique, MD PHD APHP
  More Information

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02032381     History of Changes
Other Study ID Numbers: P120137
2013-A00966-39 ( Other Identifier: APHP )
Study First Received: December 9, 2013
Last Updated: October 11, 2016

Keywords provided by Assistance Publique - Hôpitaux de Paris:
non infectious pulmonary complications after hematopoietic cell transplant
functional respiratory test and exercise test
thoracic tomodensitometry

Additional relevant MeSH terms:
Pneumonia
Bronchiolitis
Thrombosis
Respiratory Insufficiency
Pulmonary Valve Insufficiency
Bronchiolitis Obliterans
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Bronchitis
Bronchial Diseases
Lung Diseases, Obstructive
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Respiration Disorders
Heart Valve Diseases
Heart Diseases

ClinicalTrials.gov processed this record on August 22, 2017